



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	387759	Debloat and Digest+
ARTG entry for	Medicine Listed	
Sponsor	Ora Health Pty Ltd	
Postal Address	24/10-18 Orchard Road, Brookvale, NSW, 2100 Australia	
ARTG Start Date	2/05/2022	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Products

1 . Debloat and Digest+

Product Type	Single Medicine Product	Effective Date	2/05/2022
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

Maintain/support general health and wellbeing
Traditionally used in Western herbal medicine to decrease/reduce/relieve colic (wind/gas pain)
Traditionally used in Western herbal medicine to decrease/reduce/relieve flatulence/carminative
Maintain/support healthy digestive system function
Maintain/support healthy digestion
Aid/assist digestion/breakdown of dietary fat
Aid/assist digestion of glucose/sugar/carbohydrates
Aid/assist/helps digestion of (state nutrient)
Maintain/support digestive system health
Helps reduce occurrence of symptoms of indigestion/dyspepsia
Decrease/reduce/relieve abdominal bloating/distention
Traditionally used in Western herbal medicine to decrease/reduce/relieve abdominal bloating/distention
Helps reduce occurrence of abdominal bloating
Decrease/reduce/relieve abdominal feeling of fullness
Decrease/reduce/relieve abdominal pain/discomfort
Relieve excessive belching
Decrease/reduce/relieve symptoms of indigestion/dyspepsia
Traditionally used in Western herbal medicine to decrease/reduce/relieve symptoms of indigestion/dyspepsia
Decrease/reduce/relieve symptoms of heartburn

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.
Product presentation must not imply or refer to gastro oesophageal reflux disease.
If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.
Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Do not use if pregnant or likely to become pregnant (or words to that effect)
Use in children under 12 years is not recommended.
Do not use while breastfeeding.
Contains sulfites' (or words to this effect) if medicine contains two or more sulfite sources or 'Contains (insert the approved name of sulfites used)' (or words to this effect) if medicine contains one sulfite source.
If symptoms persist consult your healthcare practitioner (or words to that effect).



Australian Government
Department of Health
Therapeutic Goods Administration

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

Amylase	1.5 thousand DU
bromelains	.45 million PU
cellulase	150 CU
Foeniculum vulgare seed Extract dry concentrate	100 mg
Equivalent: Foeniculum vulgare (Dry)	1000 mg
Glycyrrhiza glabra root Extract dry concentrate standardised	75 mg
Equivalent: Glycyrrhiza glabra (Dry)	2062.5 mg
lipase	100 LipU
papain	8 mg
protease	1.8 Thousand HUT

Other Ingredients (Excipients)

colloidal anhydrous silica
dextrin
hypromellose
magnesium stearate
maltodextrin
microcrystalline cellulose
purified water
sodium metabisulfite

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary